Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)HS Rugo, SM Tolaney, Peter Kabos et al.|Cancer Research|2018Cited by 16
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIALDouglas Yee, Si Fan, A. DeMichele et al.|Cancer Research|2018Cited by 16
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancerJosé Baselga, HS Rugo, KJ Ruddy et al.|Cancer Research|2013Cited by 3
Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastasesRE Coleman, HS Rugo, Georgeta Fried et al.|Cancer Research|2017Cited by 2